GILD Obtains Positive CHMP Opinion for Liver Disease Drug

Published on 16 Dec 2024 on Zacks · via Yahoo Finance

The CHMP recommends the approval of Gilead's seladelpar in combination with ursodeoxycholic acid for...

Read the rest of the article

Start tracking your investments with Statfolio

Free Report) has put up a steady performance in 2024 amid a volatile market. Gilead has a...

Zacks 20 Dec 2024

This deal is expected to reduce Gilead’s 2024 GAAP and non-GAAP EPS by about 1 cent. Gilead...

Zacks · via Yahoo Finance 18 Dec 2024

It was a busy week in the biotech sector with lots of regulatory and pipeline updates. Among...

Zacks · via Yahoo Finance 18 Dec 2024

A new long-acting preventive HIV drug could reach the world’s poorest countries by the end of 202...

Reuters 17 Dec 2024

The CHMP recommends the approval of Gilead's seladelpar in combination with ursodeoxycholic acid ...

Zacks · via Yahoo Finance 16 Dec 2024

The Institute for Clinical and Economic Review (ICER) has identified five prescription drugs whos...

Benzinga · via Yahoo Finance 13 Dec 2024

At the HIV Analyst & Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) revealed that ...

Benzinga · via AOL 12 Dec 2024

This pharma stock could easily gain 20% next year, Jefferies says

Investing.com 11 Dec 2024

Stocks recently featured in the blog include: Eli Lilly and Co. LLY, AbbVie Inc. ABBV, Gilead...

Zacks · via Yahoo Finance 10 Dec 2024

Gilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a...

Zacks · via Yahoo Finance 4 Dec 2024